Product image of Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Kit

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Kit, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to stimulate ovarian follicular development, estrogen production and ovulation in women with infertility related to anovulation.

GNH India supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Slovakia S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Kit, containing FSH and LH, is used in reproductive medicine to support ovarian function.

  • Infertility due to anovulation: promotes follicle growth and ovulation to improve chances of conception.
  • Assisted reproductive technology (ART): enhances ovarian response during IVF or ICSI cycles.
  • Induction of ovulation: initiates ovulation in patients with hormonal insufficiency.

How It Works

  • Follicle‑Stimulating Hormone and Luteinising Hormone bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular maturation and estradiol synthesis, while LH receptor activation triggers androgen production and final oocyte maturation, culminating in ovulation.

Side Effects

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Abdominal discomfort: transient bloating or cramping.
  • Headache: mild to moderate intensity.
  • Nausea: occasional upset stomach.
  • Breast tenderness: mild swelling or soreness.
  • Mild ovarian hyperstimulation: modest increase in ovarian size.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, or respiratory distress.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Multiple pregnancy: twins or higher-order gestations.
  • Ectopic pregnancy: implantation outside the uterus.
  • Severe abdominal pain: possible ovarian torsion or rupture.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient suitability and monitor response.

  • Assess ovarian reserve: perform ultrasound and hormonal testing.
  • Monitor estradiol levels: check serum concentrations during stimulation.
  • Avoid in uncontrolled thyroid disease: correct thyroid dysfunction first.
  • Use caution with ovarian cysts: assess size and nature before treatment.
  • Contraindicated in pregnancy: do not administer to pregnant women.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions should be reviewed prior to prescribing.

Major Interactions (Avoid)

  • Concurrent hCG administration: may markedly increase risk of severe ovarian hyperstimulation.
  • High‑dose estrogen therapy: can alter gonadotropin response and increase thrombotic risk.
  • Combination with other gonadotropins: may cause excessive ovarian stimulation.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may affect hormone metabolism and response.
  • Thyroid hormone replacement: monitor thyroid function tests.
  • Antihypertensive agents: watch for blood pressure fluctuations.
  • Anticoagulants: increased bleeding risk if invasive procedures are performed.
  • NSAIDs: may mask signs of ovarian hyperstimulation.

Frequently Asked Questions

Meriofert Kit contains follicle‑stimulating hormone and luteinising hormone and is used to treat infertility caused by anovulation, to support ovarian stimulation in assisted reproductive technology cycles, and to induce ovulation in women with hormonal insufficiency.

The two hormones bind to specific receptors on ovarian cells. FSH promotes growth and maturation of ovarian follicles and stimulates estrogen production, while LH triggers androgen synthesis and final oocyte maturation, together leading to ovulation.

The dose of Meriofert Kit is individualized. A qualified prescriber determines the amount, frequency and duration of treatment based on the patient’s ovarian response, body weight and the specific fertility protocol.

Meriofert Kit is contraindicated in pregnancy because it is intended to induce ovulation. Safety during breastfeeding has not been established, and the product should only be used under medical supervision before conception.

To place an order, submit an enquiry on the Meriofert Kit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meriofert Kit combines both FSH and LH in a single injectable, whereas some alternatives provide only FSH or require separate LH administration. This combination can simplify protocols and may improve follicular response in certain patients, but the choice depends on individual clinical assessment.

Meriofert Kit should be stored at 2‑8 °C (refrigerated). Keep it in the original packaging, protect it from light, and avoid freezing or shaking the vial to maintain potency.

The product is supplied as a sterile injectable solution for subcutaneous injection. Administration is performed by a trained healthcare professional, typically in a clinical setting, following the prescriber’s dosing schedule.

The most serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, allergic reactions such as anaphylaxis, multiple pregnancy, and ectopic pregnancy. Patients should be monitored closely for these complications.

Meriofert Kit should not be used by women who are already pregnant, have uncontrolled thyroid disease, active ovarian cysts larger than 3 cm, known hypersensitivity to gonadotropins, or a history of severe ovarian hyperstimulation syndrome.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 8 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT